<DOC>
	<DOCNO>NCT01237587</DOCNO>
	<brief_summary>The purpose study determine whether duloxetine safe effective treatment adolescent Juvenile Primary Fibromyalgia Syndrome ( JPFS ) . This trial consist two distinct study period . A blinded treatment period 13 week open label extension period 26 week .</brief_summary>
	<brief_title>A Study Duloxetine Adolescents With Juvenile Primary Fibromyalgia Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria Meet criterion primary JPFS Have score great equal 4 Brief Pain Inventory ( BPI ) average pain severity ( Item 3 ) screen Female participant must negative serum pregnancy test screen Participant 's parent/legal representative participant judge reliable keep appointment clinical test procedures Participant 's parent/legal representative participant must degree understand communicate intelligently Participants must capable swallow investigational product whole Participants must venous access sufficient allow blood sample compliant blood draw Currently enrol , discontinue within last 30 day , clinical trial involve investigational drug device offlabel use drug device concurrently enrol type medical research Previously complete withdrawn randomization study investigate duloxetine Known hypersensitivity duloxetine inactive ingredient , frequent severe allergic reaction multiple medication Treated duloxetine within last 6 month . Will likely benefit duloxetine treatment , opinion investigator prior nonresponse inadequate tolerance duloxetine Pain symptom relate traumatic injury , past surgery , structural bone joint disease regional pain syndrome interfere interpretation outcome measure Currently evidence rheumatologic disorder current diagnosis rheumatoid arthritis , inflammatory arthritis , infectious arthritis , autoimmune disease ( example , systemic lupus erythematosus ) Have Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) Axis I condition , currently within past year , except major depressive disorder ( MDD ) and/or generalize anxiety disorder ( GAD ) , adjustment disorder specific phobias primary investigator approval Have current secondary DSMIV Axis I condition attentiondeficit/hyperactivity disorder require pharmacologic treatment Lifetime DSMIV Axis I diagnosis psychosis , bipolar disorder , schizoaffective disorder DSMIV Axis II disorder would interfere protocol compliance History substance abuse dependence within 6 month Positive urine drug screen substance abuse exclude medication Family history 1 firstdegree relative diagnose bipolar I disorder Significant suicide attempt within 1 year screen currently suicidal risk opinion investigator Weight le 20 kilogram ( kg ) screen History seizure disorder ( febrile seizure ) Taking excluded medication discontinue screen Fluoxetine within 30 day prior completion screen Monoamine oxidase inhibitor ( MAOI ) within 14 day screen ; potential need use MAOI study within 5 day discontinuation investigational product Abnormal thyroidstimulating hormone ( TSH ) concentration Uncontrolled narrowangle glaucoma Acute liver injury ( hepatitis ) severe cirrhosis ( ChildPugh Class C ) Serious unstable medical illness Female participant either pregnant , nurse recently give birth</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Adolescents</keyword>
	<keyword>Juvenile Primary Fibromyalgia Syndrome</keyword>
</DOC>